Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants

• Type: Article in International Scientific Journal
• Date: 2016

Authors

Shi, XG (Author) Other; Liu, RY (Author) Other; Basolo, F (Author) Other; Giannini, R (Author) Other; Shen, XP (Author) Other; Teng, D (Author) Other; Guan, HX (Author) Other; Shan, ZY (Author) Other; Teng, WP (Author) Other; Musholt, TJ (Author) Other; Al Kuraya, K (Author) Other; Fugazzola, L (Author) Other; Colombo, C (Author) Other; Kebebew, E (Author) Other; Jarzab, B (Author) Other; Czarniecka, A (Author) Other; Bendlova, B (Author) Other; Sykorova, V (Author) Other; Sobrinho Simoes, M (Author) FMUP; Soares, P (Author) FMUP; Shong, YK (Author) Other; Kim, TY (Author) Other; Cheng, S (Author) Other; Asa, SL (Author) Other; Viola, D (Author) Other; Elisei, R (Author) Other; Yip, L (Author) Other; Mian, C (Author) Other; Vianello, F (Author) Other; Wang, YG (Author) Other; Zhao, SH (Author) Other; Oler, G (Author) Other; Cerutti, JM (Author) Other; Puxeddu, E (Author) Other; Qu, S (Author) Other; Wei, Q (Author) Other; Xu, HX (Author) Other; O'Neill, CJ (Author) Other; Sywak, MS (Author) Other; Clifton Bligh, R (Author) Other; Lam, AK (Author) Other; Riesco Eizaguirre, G (Author) Other; Santisteban, P (Author) Other; Yu, HY (Author) Other; Tallini, G (Author) Other; Holt, EH (Author) Other; Vasko, V (Author) Other; Xing, MZ (Author) Other

Journal

Title: Journal of Clinical Endocrinology and Metabolism

Vol. 101

Pages: 263-273

ISSN: 0021-972X

Publisher: Endocrine Society

Indexing

ISI Web of Knowledge - 157 Citations

Scopus - 169 Citations

Other information

Authenticus ID: P-00K-3R1

DOI: 10.1210/jc.2015-2917

Abstract (EN): Context: Individualized management, incorporating papillary thyroid cancer (PTC) variant-specific risk, is conceivably a useful treatment strategy for PTC, which awaits comprehensive data demonstrating differential risks of PTC variants to support. Objective: This study sought to establish the differential clinicopathological risk of major PTC variants: conventional PTC (CPTC), follicular-variant PTC (FVPTC), and tall-cell PTC (TCPTC). Methods: This was a retrospective study of clinicopathological outcomes of 6282 PTC patients (4799 females and 1483 males) from 26 centers and The Cancer Genome Atlas in 14 countries with a median age of 44 years (interquartile range, 33-56 y) and median follow-up time of 37 months (interquartile range, 15-82 mo). Results: The cohort consisted of 4702 (74.8%) patients with CPTC, 1126 (17.9%) with FVPTC, and 239 (3.8%) with TCPTC. The prevalence of high-risk parameters was significantly different among the three variants, including extrathyroidal invasion, lymph node metastasis, stages III/IV, disease recurrence, mortality, and the use (need) of radioiodine treatment (all P < .001), being highest in TCPTC, lowest in FVPTC, and intermediate in CPTC, following an order of TCPTC > CPTC >> FVPTC. Recurrence and mortality in TCPTC, CPTC, and FVPTC were 27.3 and 6.7%, 16.1 and 2.5%, and 9.1 and 0.6%, corresponding to events per 1000 person-years (95% confidence interval [CI]) of 92.47 (64.66-132.26) and 24.61 (12.31-49.21), 34.46 (30.71-38.66), and 5.87 (4.37-7.88), and 24.73 (18.34-33.35) and 1.68 (0.54-5.21), respectively. Mortality hazard ratios of CPTC and TCPTC over FVPTC were 3.44 (95% CI, 1.07-11.11) and 14.96 (95% CI, 3.93-56.89), respectively. Kaplan-Meier survival analyses showed the best prognosis in FVPTC, worst in TCPTC, and intermediate in CPTC in disease recurrence-free probability and disease-specific patient survival. This was particularly the case in patients at least 45 years old. Conclusion: This large multicenter study demonstrates differential prognostic risks of the three major PTC variants and establishes a unique risk order of TCPTC > CPTC >> FVPTC, providing important clinical implications for specific variant-based management of PTC.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 11